Lantheus Announces Collaboration to Provide Novel Tau Imaging Agent for Large Consortium Clinical Trial Sponsored by the National Institute on Aging
The CLARiTI study will involve all 37 Alzheimer’s Disease Research Centers in
“This study is designed to shed light on the complex interplay of multiple pathologies contributing to dementia, ultimately advancing our understanding and treatment of this devastating condition,” said
“MK-6240 is poised to play a pivotal role in propelling Alzheimer’s diagnosis and treatment research to new heights,” said
About the CLARiTI Study
Clarity in Alzheimer’s Disease and Related Dementias Research Through Imaging (CLARiTI) is a multi-site imaging observational study that will be conducted at all 37 Alzheimer’s Disease Research Centers (ADRCs) in
Please visit https://naccdata.org/nacc-collaborations/clariti for more information about the study.
About Alzheimer’s Disease and Dementia
Alzheimer’s disease is a progressive degenerative brain disease and the most common form of dementia. Dementia is the loss of cognitive functioning and behavioral abilities to such an extent that it interferes with a person’s daily life and activities. Dementia is not a specific disease; it describes a group of symptoms that often has a mixture of etiologies. It is estimated that 6.7 million Americans age 65 and older are currently living with Alzheimer’s dementia. As the population ages, it is projected that by 2050, this number may grow to 12.7 million.1
Safe Harbor for Forward-Looking and Cautionary Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that are subject to risks and uncertainties and are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by their use of terms such as “designed,” “poised,” “potential,” “will” and other similar terms. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to materially differ from those described in the forward-looking statements. Readers are cautioned not to place undue reliance on the forward-looking statements contained herein, which speak only as of the date hereof. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law. Risks and uncertainties that could cause the Company’s actual results to materially differ from those described in the forward-looking statements are discussed in the Company’s filings with the
1Alzheimer’s Association. 2023 Alzheimer’s Disease Facts and Figures. Alzheimer’s Dement 2023;19(4). DOI 10.1002/alz.13016.
Vice President, Investor Relations
Source: Lantheus Holdings, Inc.